Insider Selling: Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Sells 32,469 Shares of Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Ted White sold 32,469 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $7.06, for a total value of $229,231.14. Following the transaction, the chief executive officer now owns 250,121 shares in the company, valued at approximately $1,765,854.26. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Verrica Pharmaceuticals Price Performance

Shares of NASDAQ VRCA traded up $0.44 during mid-day trading on Tuesday, reaching $7.50. The company had a trading volume of 287,241 shares, compared to its average volume of 191,165. The company has a quick ratio of 3.04, a current ratio of 3.17 and a debt-to-equity ratio of 29.58. Verrica Pharmaceuticals Inc. has a one year low of $2.86 and a one year high of $11.41. The business’s 50-day simple moving average is $8.15 and its 200 day simple moving average is $6.75.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.10. The company had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $2.70 million. Verrica Pharmaceuticals had a negative return on equity of 229.26% and a negative net margin of 905.83%. As a group, sell-side analysts forecast that Verrica Pharmaceuticals Inc. will post -1.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on VRCA shares. HC Wainwright increased their price objective on Verrica Pharmaceuticals from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Needham & Company LLC increased their price objective on Verrica Pharmaceuticals from $8.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th.

Institutional Trading of Verrica Pharmaceuticals

Large investors have recently bought and sold shares of the business. BML Capital Management LLC boosted its stake in Verrica Pharmaceuticals by 20.0% in the fourth quarter. BML Capital Management LLC now owns 180,000 shares of the company’s stock valued at $1,318,000 after buying an additional 30,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Verrica Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock valued at $7,511,000 after buying an additional 7,609 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Verrica Pharmaceuticals by 35.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 3,999,999 shares of the company’s stock valued at $29,280,000 after buying an additional 1,045,935 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its stake in Verrica Pharmaceuticals by 40.9% in the fourth quarter. Perceptive Advisors LLC now owns 7,099,182 shares of the company’s stock valued at $51,966,000 after buying an additional 2,060,199 shares in the last quarter. 42.45% of the stock is owned by institutional investors and hedge funds.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.